724 related articles for article (PubMed ID: 9100543)
1. Effusion cytology of malignant melanoma. A morphologic and immunocytochemical analysis including application of the MART-1 antibody.
Beaty MW; Fetsch P; Wilder AM; Marincola F; Abati A
Cancer; 1997 Feb; 81(1):57-63. PubMed ID: 9100543
[TBL] [Abstract][Full Text] [Related]
2. Melanoma metastatic to the breast: utility of fine needle aspiration and immunohistochemistry.
Filie AC; Simsir A; Fetsch P; Abati A
Acta Cytol; 2002; 46(1):13-8. PubMed ID: 11843553
[TBL] [Abstract][Full Text] [Related]
3. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
Conner JR; Cibas ES; Hornick JL; Qian X
Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880
[TBL] [Abstract][Full Text] [Related]
4. Utility of Sry-Related HMG-Box Gene 10 (SOX10) as a marker of melanoma in effusion cytology.
Dermawan JKT; Underwood D; Policarpio-Nicolas ML
Diagn Cytopathol; 2019 Jul; 47(7):653-658. PubMed ID: 30794352
[TBL] [Abstract][Full Text] [Related]
5. Cytologic Findings in Serous Effusion Specimens from Melanoma Patients.
Shield PW; Ribu DL
Acta Cytol; 2023; 67(5):557-563. PubMed ID: 36996775
[TBL] [Abstract][Full Text] [Related]
6. Cytologic diagnosis of melanoma in serous effusions. A morphologic and immunocytochemical study.
Longatto Filho A; de Carvalho LV; Santos Gda C; Oyafuso MS; Lombardo V; Bortolan J; Neves JI
Acta Cytol; 1995; 39(3):481-4. PubMed ID: 7762336
[TBL] [Abstract][Full Text] [Related]
7. Assessment of immunocytochemical and histochemical stainings in the distinction between reactive mesothelial cells and adenocarcinoma cells in body effusions.
Chen CJ; Chang SC; Tseng HH
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Sep; 54(3):149-55. PubMed ID: 7954054
[TBL] [Abstract][Full Text] [Related]
8. Effusion cytomorphology and immunocytochemistry of malignant melanoma: five cases of melanotic melanoma and one case of amelanotic melanoma.
Ikeda K; Tate G; Iezumi K; Suzuki T; Kitamura T; Mitsuya T
Diagn Cytopathol; 2009 Jul; 37(7):516-21. PubMed ID: 19301358
[TBL] [Abstract][Full Text] [Related]
9. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
10. Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration.
Fetsch PA; Marincola FM; Filie A; Hijazi YM; Kleiner DE; Abati A
Cancer; 1999 Feb; 87(1):37-42. PubMed ID: 10096358
[TBL] [Abstract][Full Text] [Related]
11. Metastatic epithelioid hemangioendothelioma in a pleural effusion: diagnosis by cytology.
Abati A; Cajigas A; Hijazi YM
Diagn Cytopathol; 1994; 11(1):64-7. PubMed ID: 7956664
[TBL] [Abstract][Full Text] [Related]
12. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
Hafez NH; Tahoun NS
J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
[TBL] [Abstract][Full Text] [Related]
15. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
16. [Use of immunohistochemistry in clinical cytology].
Weintraub D; Weintraub J; Vassilakos P
Ann Pathol; 1987; 7(1):25-30. PubMed ID: 3304314
[TBL] [Abstract][Full Text] [Related]
17. Kba.62 and S100 protein expression in cytologic samples of metastatic malignant melanoma.
Erdag G; Chowdhuri SR; Fetsch P; Erickson D; Hughes MS; Filie AC
Diagn Cytopathol; 2013 Oct; 41(10):847-51. PubMed ID: 23554410
[TBL] [Abstract][Full Text] [Related]
18. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
19. EZH2, a unique marker of malignancy in effusion cytology.
Jiang H; Gupta R; Somma J
Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
